# Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes

> **NIH NIH R35** · CHILDREN'S HOSP OF PHILADELPHIA · 2021 · $1,032,000

## Abstract

Project Summary
After stunning improvements in patient outcomes for most childhood cancers in the latter half of the last
century, cure rates have plateaued. Children with metastatic solid malignancies continue to have a less than
50% chance of survival despite being treated with highly intensive cytotoxic therapies. Neuroblastoma (NB), a
diverse malignancy affecting very young children that arises from the developing sympathetic nervous system,
is responsible for a disproportionate amount of morbidity and mortality attributable to childhood cancer and is
the main focus of the Maris translational research program. Our primary motivation is to improve patient
outcomes, and we also deem NB an outstanding model of cancer in general, such that discoveries of basic
mechanisms of tumorigenesis are broadly applicable to other human malignancies. Over the next seven years,
the Maris lab will seek to substantively improve cure rates for patients with through a multidisciplinary and
collaborative research program. Our broad goal is to discover the fundamental mechanisms that subvert
normal neural development and orchestrate NB tumorigenesis, and then to translate this knowledge into
patient-specific therapies that will be more effective and less toxic. We thus have a comprehensive approach
with six highly integrated major research efforts planned over the next seven years. 1) Genetic susceptibility to
NB. Our lab has discovered the majority of NB predisposition genes using genetic approaches. We will now
define the mechanisms by which DNA variation cause malignant transformation via epistatic deregulation of
normal developmental pathways using epigenomics approaches. 2) NB genomics and clonal evolution. Our lab
has led the collaborative efforts to define the genomic landscape of diagnostic high-risk NB. We will now focus
on NB as a dynamic ecosystem, defining how tumors adapt to the selective pressure of therapy. 3) NB drug
development. The Maris lab has utilized genomic data and genetic screens to define oncogenic vulnerabilities,
and many of these have been translated to the clinic. We will now focus on defining mechanisms of therapy
resistance to both standard of care agents and the targeted therapies we develop. 4) Immunogenomics. The
Maris lab has used an integrative approach to discover several new immunotherapeutic targets in NB. We will
now intensively focus on developing antibodies, antibody drug conjugate and adoptive T-cell therapies to these
targets designed to eradicate NB safely. 5) Precision NB therapies. We have developed biomarker-directed
clinical trials for children with relapsed NB, and will continue our efforts here both in the relapse and newly
diagnosed setting using clinical trials designed to enrich for patients most likely to benefit. We think that our
research program proposes a variety of innovative experimental strategies to uncover basic mechanisms of
oncogenesis, kinome reprogramming, epigenetic adaptation and immune evasion,...

## Key facts

- **NIH application ID:** 10246427
- **Project number:** 5R35CA220500-05
- **Recipient organization:** CHILDREN'S HOSP OF PHILADELPHIA
- **Principal Investigator:** JOHN M MARIS
- **Activity code:** R35 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,032,000
- **Award type:** 5
- **Project period:** 2017-09-30 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10246427

## Citation

> US National Institutes of Health, RePORTER application 10246427, Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes (5R35CA220500-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10246427. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*